BMJ (2017) 359:j4849
Legius E, Dierick H, Wu R, Hall BK, Marynen P, Cassiman JJ, et al
390, no
What Recent Research and Regulatory Updates Show A 2024 Danish study found that adults with type 2 diabetes who used semaglutide once a week were more than twice as likely to develop NAION within five years compared with non-users (HR 2.19), with a median onset of 22 months after starting the medication
"watching the Harbor wake up is one of the best kept secrets of the Emerald Coast"
Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read Retatrutide Peptide: Benefits, Uses, Side Effects, Dosage, and Research